<SEC-DOCUMENT>0001140361-21-028093.txt : 20210812
<SEC-HEADER>0001140361-21-028093.hdr.sgml : 20210812
<ACCEPTANCE-DATETIME>20210812160054
ACCESSION NUMBER:		0001140361-21-028093
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210802
FILED AS OF DATE:		20210812
DATE AS OF CHANGE:		20210812

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38550
		FILM NUMBER:		211167365

	BUSINESS ADDRESS:	
		STREET 1:		54 RUE LA BOETIE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75008
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		54 RUE LA BOETIE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75008

	FORMER NAME:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER NAME:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Translate Bio, Inc.
		CENTRAL INDEX KEY:			0001693415
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				611807780
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		29 HARTWELL AVENUE
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		617-945-7361

	MAIL ADDRESS:	
		STREET 1:		29 HARTWELL AVENUE
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RaNA Therapeutics, Inc.
		DATE OF NAME CHANGE:	20161228
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-08-02</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001693415</issuerCik>
        <issuerName>Translate Bio, Inc.</issuerName>
        <issuerTradingSymbol>TBIO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001121404</rptOwnerCik>
            <rptOwnerName>Sanofi</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>54, RUE LA BOETIE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>PARIS</rptOwnerCity>
            <rptOwnerState>I0</rptOwnerState>
            <rptOwnerZipCode>75008</rptOwnerZipCode>
            <rptOwnerStateDescription>FRANCE</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOther>true</isOther>
            <otherText>See Remarks below</otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>3684434</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <remarks>In connection with an Agreement and Plan of Merger, dated as of August 2, 2021, by and among Sanofi, Vector Merger Sub, Inc., an indirect wholly owned subsidiary of Sanofi, and Translate Bio, Inc. (the &quot;Issuer&quot;), Sanofi entered into Tender and Support Agreements dated as of August 2, 2021 (&quot;Tender and Support Agreements&quot;), with certain stockholders of the Issuer (the &quot;Supporting Stockholders&quot;).  As of August 2, 2021, the Reporting Person and the Supporting Stockholders collectively beneficially owned more than 10% of the outstanding shares of common stock of the Issuer. Neither the filing of this Form 3 nor any of its contents shall be deemed to constitute an admission by the Reporting Person that it is the beneficial owner of any shares beneficially owned by the Supporting Stockholders for purposes of Section 13(d) or Section 16 of the Exchange Act or for any other purpose, and the Reporting Person expressly disclaims beneficial ownership of such shares.  The Reporting Person hereby disclaims that it is a member of a &quot;group&quot; (within the meaning of Section 13(d)(3) of the Exchange Act) with the Supporting Stockholders.  Copies of the Tender and Support Agreements were filed as exhibits by the Issuer to its Form 8-K filed with the SEC on August 3, 2021.</remarks>

    <ownerSignature>
        <signatureName>/s/ Alexandra Roger, as Head of Securities Law and Capital Markets of Sanofi</signatureName>
        <signatureDate>2021-08-12</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
